{
  "ticker": "VRTX",
  "year": 2023,
  "quarter": 1,
  "last_updated": "2025-04-15T16:12:15.965878",
  "count": 228,
  "transactions": [
    {
      "id": 42964,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-03-31",
      "transaction_shares": "176",
      "transaction_price": "313.74",
      "transaction_type": "F",
      "shares_after_transaction": "7127"
    },
    {
      "id": 42968,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-03-31",
      "transaction_shares": "1466",
      "transaction_price": "313.74",
      "transaction_type": "F",
      "shares_after_transaction": "47802"
    },
    {
      "id": 76544,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-03-31",
      "transaction_shares": "176",
      "transaction_price": "313.74",
      "transaction_type": "F",
      "shares_after_transaction": "7127"
    },
    {
      "id": 76549,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-03-31",
      "transaction_shares": "1466",
      "transaction_price": "313.74",
      "transaction_type": "F",
      "shares_after_transaction": "47802"
    },
    {
      "id": 118575,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-03-31",
      "transaction_shares": "176",
      "transaction_price": "313.74",
      "transaction_type": "F",
      "shares_after_transaction": "7127"
    },
    {
      "id": 118580,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-03-31",
      "transaction_shares": "1466",
      "transaction_price": "313.74",
      "transaction_type": "F",
      "shares_after_transaction": "47802"
    },
    {
      "id": 166432,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-03-31",
      "transaction_shares": "176",
      "transaction_price": "313.74",
      "transaction_type": "F",
      "shares_after_transaction": "7127"
    },
    {
      "id": 166437,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-03-31",
      "transaction_shares": "1466",
      "transaction_price": "313.74",
      "transaction_type": "F",
      "shares_after_transaction": "47802"
    },
    {
      "id": 43017,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-24",
      "transaction_shares": "1768",
      "transaction_price": "305.38",
      "transaction_type": "S",
      "shares_after_transaction": "49611"
    },
    {
      "id": 76607,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-24",
      "transaction_shares": "1768",
      "transaction_price": "305.38",
      "transaction_type": "S",
      "shares_after_transaction": "49611"
    },
    {
      "id": 118645,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-24",
      "transaction_shares": "1768",
      "transaction_price": "305.38",
      "transaction_type": "S",
      "shares_after_transaction": "49611"
    },
    {
      "id": 166513,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-24",
      "transaction_shares": "1768",
      "transaction_price": "305.38",
      "transaction_type": "S",
      "shares_after_transaction": "49611"
    },
    {
      "id": 42932,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-17",
      "transaction_shares": "360",
      "transaction_price": "294.52",
      "transaction_type": "S",
      "shares_after_transaction": "53019"
    },
    {
      "id": 76506,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-17",
      "transaction_shares": "360",
      "transaction_price": "294.52",
      "transaction_type": "S",
      "shares_after_transaction": "53019"
    },
    {
      "id": 118532,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-17",
      "transaction_shares": "360",
      "transaction_price": "294.52",
      "transaction_type": "S",
      "shares_after_transaction": "53019"
    },
    {
      "id": 166386,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-17",
      "transaction_shares": "360",
      "transaction_price": "294.52",
      "transaction_type": "S",
      "shares_after_transaction": "53019"
    },
    {
      "id": 42957,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-03-16",
      "transaction_shares": "2482",
      "transaction_price": "300.54",
      "transaction_type": "S",
      "shares_after_transaction": "49532"
    },
    {
      "id": 76534,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-03-16",
      "transaction_shares": "2482",
      "transaction_price": "300.54",
      "transaction_type": "S",
      "shares_after_transaction": "49532"
    },
    {
      "id": 118562,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-03-16",
      "transaction_shares": "2482",
      "transaction_price": "300.54",
      "transaction_type": "S",
      "shares_after_transaction": "49532"
    },
    {
      "id": 166417,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-03-16",
      "transaction_shares": "2482",
      "transaction_price": "300.54",
      "transaction_type": "S",
      "shares_after_transaction": "49532"
    },
    {
      "id": 42946,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-10",
      "transaction_shares": "361",
      "transaction_price": "286.64",
      "transaction_type": "S",
      "shares_after_transaction": "57772"
    },
    {
      "id": 76521,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-10",
      "transaction_shares": "361",
      "transaction_price": "286.64",
      "transaction_type": "S",
      "shares_after_transaction": "57772"
    },
    {
      "id": 118548,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-10",
      "transaction_shares": "361",
      "transaction_price": "286.64",
      "transaction_type": "S",
      "shares_after_transaction": "57772"
    },
    {
      "id": 166402,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-03-10",
      "transaction_shares": "361",
      "transaction_price": "286.64",
      "transaction_type": "S",
      "shares_after_transaction": "57772"
    },
    {
      "id": 42941,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3970",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "52014"
    },
    {
      "id": 42943,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "2468",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "66518"
    },
    {
      "id": 42982,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-24",
      "transaction_shares": "13730",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "48349"
    },
    {
      "id": 42989,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "502",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "8510"
    },
    {
      "id": 42993,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3970",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "36276"
    },
    {
      "id": 42999,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "57159"
    },
    {
      "id": 43016,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "63207"
    },
    {
      "id": 43033,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "4714",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "61590"
    },
    {
      "id": 43041,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-24",
      "transaction_shares": "9386",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "129969"
    },
    {
      "id": 43042,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "58133"
    },
    {
      "id": 76516,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3970",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "52014"
    },
    {
      "id": 76518,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "2468",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "66518"
    },
    {
      "id": 76566,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-24",
      "transaction_shares": "13730",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "48349"
    },
    {
      "id": 76574,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "502",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "8510"
    },
    {
      "id": 76578,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3970",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "36276"
    },
    {
      "id": 76586,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "57159"
    },
    {
      "id": 76606,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "63207"
    },
    {
      "id": 76625,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "4714",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "61590"
    },
    {
      "id": 76634,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-24",
      "transaction_shares": "9386",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "129969"
    },
    {
      "id": 76635,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "58133"
    },
    {
      "id": 118543,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3970",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "52014"
    },
    {
      "id": 118545,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "2468",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "66518"
    },
    {
      "id": 118600,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-24",
      "transaction_shares": "13730",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "48349"
    },
    {
      "id": 118609,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "502",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "8510"
    },
    {
      "id": 118614,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3970",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "36276"
    },
    {
      "id": 118623,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "57159"
    },
    {
      "id": 118644,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "63207"
    },
    {
      "id": 118666,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "4714",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "61590"
    },
    {
      "id": 118675,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-24",
      "transaction_shares": "9386",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "129969"
    },
    {
      "id": 118676,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "58133"
    },
    {
      "id": 166397,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3970",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "52014"
    },
    {
      "id": 166399,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "2468",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "66518"
    },
    {
      "id": 166460,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-24",
      "transaction_shares": "13730",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "48349"
    },
    {
      "id": 166472,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "502",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "8510"
    },
    {
      "id": 166478,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3970",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "36276"
    },
    {
      "id": 166488,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "57159"
    },
    {
      "id": 166512,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "63207"
    },
    {
      "id": 166536,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-24",
      "transaction_shares": "4714",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "61590"
    },
    {
      "id": 166545,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-24",
      "transaction_shares": "9386",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "129969"
    },
    {
      "id": 166546,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-24",
      "transaction_shares": "3308",
      "transaction_price": "289.12",
      "transaction_type": "F",
      "shares_after_transaction": "58133"
    },
    {
      "id": 42940,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-22",
      "transaction_shares": "129",
      "transaction_price": "291.84",
      "transaction_type": "S",
      "shares_after_transaction": "68576"
    },
    {
      "id": 76515,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-22",
      "transaction_shares": "129",
      "transaction_price": "291.84",
      "transaction_type": "S",
      "shares_after_transaction": "68576"
    },
    {
      "id": 118542,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-22",
      "transaction_shares": "129",
      "transaction_price": "291.84",
      "transaction_type": "S",
      "shares_after_transaction": "68576"
    },
    {
      "id": 166396,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-22",
      "transaction_shares": "129",
      "transaction_price": "291.84",
      "transaction_type": "S",
      "shares_after_transaction": "68576"
    },
    {
      "id": 42962,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-17",
      "transaction_shares": "9359",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "139355"
    },
    {
      "id": 42971,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-17",
      "transaction_shares": "4498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "60947"
    },
    {
      "id": 42981,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "55984"
    },
    {
      "id": 42990,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "4498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "71107"
    },
    {
      "id": 42992,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "66515"
    },
    {
      "id": 43021,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "44248"
    },
    {
      "id": 43046,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "61441"
    },
    {
      "id": 43047,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "68986"
    },
    {
      "id": 76541,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-17",
      "transaction_shares": "9359",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "139355"
    },
    {
      "id": 76552,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-17",
      "transaction_shares": "4498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "60947"
    },
    {
      "id": 76565,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "55984"
    },
    {
      "id": 76575,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "4498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "71107"
    },
    {
      "id": 76577,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "66515"
    },
    {
      "id": 76612,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "44248"
    },
    {
      "id": 76640,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "61441"
    },
    {
      "id": 76641,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "68986"
    },
    {
      "id": 118571,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-17",
      "transaction_shares": "9359",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "139355"
    },
    {
      "id": 118583,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-17",
      "transaction_shares": "4498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "60947"
    },
    {
      "id": 118599,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "55984"
    },
    {
      "id": 118611,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "4498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "71107"
    },
    {
      "id": 118613,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "66515"
    },
    {
      "id": 118651,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "44248"
    },
    {
      "id": 118682,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "61441"
    },
    {
      "id": 118683,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "68986"
    },
    {
      "id": 166426,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-17",
      "transaction_shares": "9359",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "139355"
    },
    {
      "id": 166441,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-17",
      "transaction_shares": "4498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "60947"
    },
    {
      "id": 166459,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "55984"
    },
    {
      "id": 166474,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "4498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "71107"
    },
    {
      "id": 166477,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "66515"
    },
    {
      "id": 166520,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "44248"
    },
    {
      "id": 166552,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3750",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "61441"
    },
    {
      "id": 166553,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-17",
      "transaction_shares": "3498",
      "transaction_price": "292.85",
      "transaction_type": "F",
      "shares_after_transaction": "68986"
    },
    {
      "id": 42945,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-14",
      "transaction_shares": "800",
      "transaction_price": "295.84",
      "transaction_type": "S",
      "shares_after_transaction": "81203"
    },
    {
      "id": 42955,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-14",
      "transaction_shares": "800",
      "transaction_price": "295.79",
      "transaction_type": "S",
      "shares_after_transaction": "53596"
    },
    {
      "id": 42975,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-14",
      "transaction_shares": "1902",
      "transaction_price": "300.29",
      "transaction_type": "S",
      "shares_after_transaction": "60013"
    },
    {
      "id": 43015,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-14",
      "transaction_shares": "71",
      "transaction_price": "295.89",
      "transaction_type": "S",
      "shares_after_transaction": "65694"
    },
    {
      "id": 76520,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-14",
      "transaction_shares": "800",
      "transaction_price": "295.84",
      "transaction_type": "S",
      "shares_after_transaction": "81203"
    },
    {
      "id": 76532,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-14",
      "transaction_shares": "800",
      "transaction_price": "295.79",
      "transaction_type": "S",
      "shares_after_transaction": "53596"
    },
    {
      "id": 76557,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-14",
      "transaction_shares": "1902",
      "transaction_price": "300.29",
      "transaction_type": "S",
      "shares_after_transaction": "60013"
    },
    {
      "id": 76605,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-14",
      "transaction_shares": "71",
      "transaction_price": "295.89",
      "transaction_type": "S",
      "shares_after_transaction": "65694"
    },
    {
      "id": 118547,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-14",
      "transaction_shares": "800",
      "transaction_price": "295.84",
      "transaction_type": "S",
      "shares_after_transaction": "81203"
    },
    {
      "id": 118560,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-14",
      "transaction_shares": "800",
      "transaction_price": "295.79",
      "transaction_type": "S",
      "shares_after_transaction": "53596"
    },
    {
      "id": 118588,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-14",
      "transaction_shares": "1902",
      "transaction_price": "300.29",
      "transaction_type": "S",
      "shares_after_transaction": "60013"
    },
    {
      "id": 118643,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-14",
      "transaction_shares": "71",
      "transaction_price": "295.89",
      "transaction_type": "S",
      "shares_after_transaction": "65694"
    },
    {
      "id": 166401,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-14",
      "transaction_shares": "800",
      "transaction_price": "295.84",
      "transaction_type": "S",
      "shares_after_transaction": "81203"
    },
    {
      "id": 166415,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-14",
      "transaction_shares": "800",
      "transaction_price": "295.79",
      "transaction_type": "S",
      "shares_after_transaction": "53596"
    },
    {
      "id": 166447,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-14",
      "transaction_shares": "1902",
      "transaction_price": "300.29",
      "transaction_type": "S",
      "shares_after_transaction": "60013"
    },
    {
      "id": 166511,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-14",
      "transaction_shares": "71",
      "transaction_price": "295.89",
      "transaction_type": "S",
      "shares_after_transaction": "65694"
    },
    {
      "id": 42965,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-13",
      "transaction_shares": "13344",
      "transaction_price": "298.26",
      "transaction_type": "F",
      "shares_after_transaction": "62079"
    },
    {
      "id": 76545,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-13",
      "transaction_shares": "13344",
      "transaction_price": "298.26",
      "transaction_type": "F",
      "shares_after_transaction": "62079"
    },
    {
      "id": 118576,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-13",
      "transaction_shares": "13344",
      "transaction_price": "298.26",
      "transaction_type": "F",
      "shares_after_transaction": "62079"
    },
    {
      "id": 166433,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-13",
      "transaction_shares": "13344",
      "transaction_price": "298.26",
      "transaction_type": "F",
      "shares_after_transaction": "62079"
    },
    {
      "id": 42947,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-10",
      "transaction_shares": "902",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "66368"
    },
    {
      "id": 42956,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2707",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "70183"
    },
    {
      "id": 42970,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3461",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "65184"
    },
    {
      "id": 42976,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3372",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "154704"
    },
    {
      "id": 42984,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2707",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "75257"
    },
    {
      "id": 43003,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-10",
      "transaction_shares": "1377",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "69035"
    },
    {
      "id": 43023,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2611",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "77141"
    },
    {
      "id": 43031,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3372",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "92880"
    },
    {
      "id": 76522,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-10",
      "transaction_shares": "902",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "66368"
    },
    {
      "id": 76533,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2707",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "70183"
    },
    {
      "id": 76551,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3461",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "65184"
    },
    {
      "id": 76559,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3372",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "154704"
    },
    {
      "id": 76569,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2707",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "75257"
    },
    {
      "id": 76591,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-10",
      "transaction_shares": "1377",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "69035"
    },
    {
      "id": 76614,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2611",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "77141"
    },
    {
      "id": 76622,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3372",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "92880"
    },
    {
      "id": 118550,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-10",
      "transaction_shares": "902",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "66368"
    },
    {
      "id": 118561,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2707",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "70183"
    },
    {
      "id": 118582,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3461",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "65184"
    },
    {
      "id": 118591,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3372",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "154704"
    },
    {
      "id": 118604,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2707",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "75257"
    },
    {
      "id": 118628,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-10",
      "transaction_shares": "1377",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "69035"
    },
    {
      "id": 118653,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2611",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "77141"
    },
    {
      "id": 118663,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3372",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "92880"
    },
    {
      "id": 166405,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-10",
      "transaction_shares": "902",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "66368"
    },
    {
      "id": 166416,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2707",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "70183"
    },
    {
      "id": 166440,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3461",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "65184"
    },
    {
      "id": 166451,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3372",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "154704"
    },
    {
      "id": 166464,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2707",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "75257"
    },
    {
      "id": 166493,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-10",
      "transaction_shares": "1377",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "69035"
    },
    {
      "id": 166522,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sachdev Amit",
      "reporting_owner_cik": "0001406338",
      "reporting_owner_position": "EVP, Chief Patient Officer",
      "transaction_date": "2023-02-10",
      "transaction_shares": "2611",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "77141"
    },
    {
      "id": 166533,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-10",
      "transaction_shares": "3372",
      "transaction_price": "294.33",
      "transaction_type": "F",
      "shares_after_transaction": "92880"
    },
    {
      "id": 42972,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-06",
      "transaction_shares": "1304",
      "transaction_price": "187.53",
      "transaction_type": "M",
      "shares_after_transaction": "69949"
    },
    {
      "id": 76553,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-06",
      "transaction_shares": "1304",
      "transaction_price": "187.53",
      "transaction_type": "M",
      "shares_after_transaction": "69949"
    },
    {
      "id": 118584,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-06",
      "transaction_shares": "1304",
      "transaction_price": "187.53",
      "transaction_type": "M",
      "shares_after_transaction": "69949"
    },
    {
      "id": 166443,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-06",
      "transaction_shares": "1304",
      "transaction_price": "187.53",
      "transaction_type": "M",
      "shares_after_transaction": "69949"
    },
    {
      "id": 42929,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "70419"
    },
    {
      "id": 42930,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Biller Jonathan",
      "reporting_owner_cik": "0001744749",
      "reporting_owner_position": "EVP and Chief Legal Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "6293",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "11587"
    },
    {
      "id": 42949,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-01",
      "transaction_shares": "9092",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "47090"
    },
    {
      "id": 42954,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "48465"
    },
    {
      "id": 42961,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-01",
      "transaction_shares": "31462",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "33885"
    },
    {
      "id": 42969,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "2566",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "6062"
    },
    {
      "id": 42979,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "101986"
    },
    {
      "id": 43019,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "10324",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "53188"
    },
    {
      "id": 43029,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "10324",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "59836"
    },
    {
      "id": 43038,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-01",
      "transaction_shares": "6194",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "52284"
    },
    {
      "id": 76503,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "70419"
    },
    {
      "id": 76504,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Biller Jonathan",
      "reporting_owner_cik": "0001744749",
      "reporting_owner_position": "EVP and Chief Legal Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "6293",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "11587"
    },
    {
      "id": 76524,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-01",
      "transaction_shares": "9092",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "47090"
    },
    {
      "id": 76531,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "48465"
    },
    {
      "id": 76539,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-01",
      "transaction_shares": "31462",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "33885"
    },
    {
      "id": 76550,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "2566",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "6062"
    },
    {
      "id": 76562,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "101986"
    },
    {
      "id": 76609,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "10324",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "53188"
    },
    {
      "id": 76620,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "10324",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "59836"
    },
    {
      "id": 76631,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-01",
      "transaction_shares": "6194",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "52284"
    },
    {
      "id": 118528,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "70419"
    },
    {
      "id": 118529,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Biller Jonathan",
      "reporting_owner_cik": "0001744749",
      "reporting_owner_position": "EVP and Chief Legal Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "6293",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "11587"
    },
    {
      "id": 118552,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-01",
      "transaction_shares": "9092",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "47090"
    },
    {
      "id": 118559,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "48465"
    },
    {
      "id": 118569,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-01",
      "transaction_shares": "31462",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "33885"
    },
    {
      "id": 118581,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "2566",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "6062"
    },
    {
      "id": 118596,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "101986"
    },
    {
      "id": 118647,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "10324",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "53188"
    },
    {
      "id": 118660,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "10324",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "59836"
    },
    {
      "id": 118672,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-01",
      "transaction_shares": "6194",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "52284"
    },
    {
      "id": 166382,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Arbuckle Stuart A",
      "reporting_owner_cik": "0001557290",
      "reporting_owner_position": "EVP, COO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "70419"
    },
    {
      "id": 166383,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Biller Jonathan",
      "reporting_owner_cik": "0001744749",
      "reporting_owner_position": "EVP and Chief Legal Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "6293",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "11587"
    },
    {
      "id": 166407,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-02-01",
      "transaction_shares": "9092",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "47090"
    },
    {
      "id": 166414,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "ALTSHULER DAVID",
      "reporting_owner_cik": "0001550395",
      "reporting_owner_position": "EVP, Global Research and CSO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "48465"
    },
    {
      "id": 166424,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "LEIDEN JEFFREY M",
      "reporting_owner_cik": "0001242825",
      "reporting_owner_position": "Executive Chairman",
      "transaction_date": "2023-02-01",
      "transaction_shares": "31462",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "33885"
    },
    {
      "id": 166438,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Ambrose Kristen",
      "reporting_owner_cik": "0001856587",
      "reporting_owner_position": "SVP & Chief Accounting Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "2566",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "6062"
    },
    {
      "id": 166456,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-02-01",
      "transaction_shares": "12388",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "101986"
    },
    {
      "id": 166516,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "WAGNER CHARLES F JR",
      "reporting_owner_cik": "0001223348",
      "reporting_owner_position": "EVP & Chief Financial Officer",
      "transaction_date": "2023-02-01",
      "transaction_shares": "10324",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "53188"
    },
    {
      "id": 166530,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Bozic Carmen",
      "reporting_owner_cik": "0001790029",
      "reporting_owner_position": "EVP and CMO",
      "transaction_date": "2023-02-01",
      "transaction_shares": "10324",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "59836"
    },
    {
      "id": 166542,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Tatsis Ourania",
      "reporting_owner_cik": "0001789815",
      "reporting_owner_position": "EVP, Chief Reg. & Quality Off.",
      "transaction_date": "2023-02-01",
      "transaction_shares": "6194",
      "transaction_price": "0.00",
      "transaction_type": "A",
      "shares_after_transaction": "52284"
    },
    {
      "id": 42944,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "SACHS BRUCE I",
      "reporting_owner_cik": "0001197036",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-31",
      "transaction_shares": "1200",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "42410"
    },
    {
      "id": 43032,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-01-31",
      "transaction_shares": "106",
      "transaction_price": "325.00",
      "transaction_type": "S",
      "shares_after_transaction": "37998"
    },
    {
      "id": 76519,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "SACHS BRUCE I",
      "reporting_owner_cik": "0001197036",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-31",
      "transaction_shares": "1200",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "42410"
    },
    {
      "id": 76624,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-01-31",
      "transaction_shares": "106",
      "transaction_price": "325.00",
      "transaction_type": "S",
      "shares_after_transaction": "37998"
    },
    {
      "id": 118546,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "SACHS BRUCE I",
      "reporting_owner_cik": "0001197036",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-31",
      "transaction_shares": "1200",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "42410"
    },
    {
      "id": 118665,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-01-31",
      "transaction_shares": "106",
      "transaction_price": "325.00",
      "transaction_type": "S",
      "shares_after_transaction": "37998"
    },
    {
      "id": 166400,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "SACHS BRUCE I",
      "reporting_owner_cik": "0001197036",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-31",
      "transaction_shares": "1200",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "42410"
    },
    {
      "id": 166535,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Sanna Bastiano",
      "reporting_owner_cik": "0001829069",
      "reporting_owner_position": "EVP, Cell & Genetic Therapies",
      "transaction_date": "2023-01-31",
      "transaction_shares": "106",
      "transaction_price": "325.00",
      "transaction_type": "S",
      "shares_after_transaction": "37998"
    },
    {
      "id": 43028,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "CARNEY LLOYD",
      "reporting_owner_cik": "0001204424",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-30",
      "transaction_shares": "1376",
      "transaction_price": "320.08",
      "transaction_type": "S",
      "shares_after_transaction": "5474"
    },
    {
      "id": 76619,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "CARNEY LLOYD",
      "reporting_owner_cik": "0001204424",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-30",
      "transaction_shares": "1376",
      "transaction_price": "320.08",
      "transaction_type": "S",
      "shares_after_transaction": "5474"
    },
    {
      "id": 118659,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "CARNEY LLOYD",
      "reporting_owner_cik": "0001204424",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-30",
      "transaction_shares": "1376",
      "transaction_price": "320.08",
      "transaction_type": "S",
      "shares_after_transaction": "5474"
    },
    {
      "id": 166529,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "CARNEY LLOYD",
      "reporting_owner_cik": "0001204424",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-30",
      "transaction_shares": "1376",
      "transaction_price": "320.08",
      "transaction_type": "S",
      "shares_after_transaction": "5474"
    },
    {
      "id": 43039,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-27",
      "transaction_shares": "1429",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "3304"
    },
    {
      "id": 76632,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-27",
      "transaction_shares": "1429",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "3304"
    },
    {
      "id": 118673,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-27",
      "transaction_shares": "1429",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "3304"
    },
    {
      "id": 166543,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-27",
      "transaction_shares": "1429",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "3304"
    },
    {
      "id": 42966,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-01-25",
      "transaction_shares": "10000",
      "transaction_price": "315.05",
      "transaction_type": "S",
      "shares_after_transaction": "89598"
    },
    {
      "id": 43030,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-25",
      "transaction_shares": "4000",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "5875"
    },
    {
      "id": 76546,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-01-25",
      "transaction_shares": "10000",
      "transaction_price": "315.05",
      "transaction_type": "S",
      "shares_after_transaction": "89598"
    },
    {
      "id": 76621,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-25",
      "transaction_shares": "4000",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "5875"
    },
    {
      "id": 118577,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-01-25",
      "transaction_shares": "10000",
      "transaction_price": "315.05",
      "transaction_type": "S",
      "shares_after_transaction": "89598"
    },
    {
      "id": 118662,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-25",
      "transaction_shares": "4000",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "5875"
    },
    {
      "id": 166434,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Kewalramani Reshma",
      "reporting_owner_cik": "0001735944",
      "reporting_owner_position": "CEO & President",
      "transaction_date": "2023-01-25",
      "transaction_shares": "10000",
      "transaction_price": "315.05",
      "transaction_type": "S",
      "shares_after_transaction": "89598"
    },
    {
      "id": 166532,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-25",
      "transaction_shares": "4000",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "5875"
    },
    {
      "id": 43004,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-23",
      "transaction_shares": "2129",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "4004"
    },
    {
      "id": 76592,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-23",
      "transaction_shares": "2129",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "4004"
    },
    {
      "id": 118629,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-23",
      "transaction_shares": "2129",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "4004"
    },
    {
      "id": 166494,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-23",
      "transaction_shares": "2129",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "4004"
    },
    {
      "id": 43002,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-17",
      "transaction_shares": "4000",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "5875"
    },
    {
      "id": 76589,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-17",
      "transaction_shares": "4000",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "5875"
    },
    {
      "id": 118626,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-17",
      "transaction_shares": "4000",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "5875"
    },
    {
      "id": 166491,
      "issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
      "reporting_owner": "Lee Yuchun",
      "reporting_owner_cik": "0001334365",
      "reporting_owner_position": null,
      "transaction_date": "2023-01-17",
      "transaction_shares": "4000",
      "transaction_price": "72.14",
      "transaction_type": "M",
      "shares_after_transaction": "5875"
    }
  ]
}